Expert Review of Endocrinology and Metabolism This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Is inverse association between lipoprotein(a) and diabetes mellitus another paradox in cardiometabolic medicine?
Expert Rev Endocrinol Metab. 2023 Dec 11:1-8. doi: 10.1080/17446651.2023.2293108. Online ahead of print.ABSTRACTINTRODUCTION: The impact of Type II Diabetes mellitus (T2DM) on cardiovascular disease (CVD) is well-established, while lipoprotein(a) [Lp(a)] has recently emerged as a recognized CVD risk factor. The rising prevalence of T2DM resulting from modern lifestyles and the development of specific Lp(a)-lowering agents brought the association between T2DM and Lp(a) in the forefront.AREAS COVERED: Despite advancements in T2DM treatment, diabetic patients remain at very-high risk of CVD. Lp(a) may, to some extent, contrib...
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Donatos Tsamoulis Constantine E Kosmas Loukianos S Rallidis Source Type: research

Biomarkers of response to treatment in acromegaly
Expert Rev Endocrinol Metab. 2023 Dec 11:1-11. doi: 10.1080/17446651.2023.2293107. Online ahead of print.ABSTRACTINTRODUCTION: Medical treatment of acromegaly is based in a `trial and error` approach. First-generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical therapy to the vast majority of patients, despite lack of disease control in approximately 60% of patients. However, other drugs used in acromegaly treatment are available (cabergoline, pasireotide and pegvisomant).AREAS COVERED: In this article, we review and discuss the biomarkers of response to medical treatment in acromegaly.EXPER...
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Leandro Kasuki Elisa Lamback Ximene Antunes M ônica R Gadelha Source Type: research

Advancements in pharmacotherapy options for treating diabetes ‎in children and adolescents
This study compares diabetes management between pediatric and adult patients and identifies treatment challenges and gaps.AREAS COVERED: We searched PubMed and Clinicaltrails.gov databases for studies published from 2001 to 2023 on diabetes management in different age groups.EXPERT OPINION: Research shows children have lower insulin sensitivity, clearance, and β cell function than adults. The US FDA only allows insulin, metformin, and liraglutide as antidiabetic medication options for children. However, some off-label drugs, like meglitinides, sulfonylureas, and alogliptin, have demonstrated positive results in treating c...
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Marzieh Daniali Shekoufeh Nikfar Mohammad Abdollahi Source Type: research

Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study
CONCLUSION: Teneligliptin seems to be cost-effective and safer option in T2DM subjects who were not adequately controlled with metformin and sulfonylureas. However, further prospective studies are needed.PMID:38078453 | DOI:10.1080/17446651.2023.2290486 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - December 11, 2023 Category: Endocrinology Authors: Harmanjit Singh Ravi Rohilla Shivani Jaswal Mandeep Singla Source Type: research

Assessment of liver enzymes as diagnostic biomarkers in type 2 diabetes mellitus: a cross-sectional study in Zakho, Iraq
CONCLUSIONS: The study emphasizes the diagnostic importance of liver enzymes in individuals with type 2 diabetes, suggesting that these biomarkers could be valuable indicators of disease severity and progression.PMID:38050336 | DOI:10.1080/17446651.2023.2291146 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - December 5, 2023 Category: Endocrinology Authors: Dilveen Y Ahmed Lina N Adam Resan A Ahmed Mohammed K Mirza Source Type: research

Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials
CONCLUSIONS: Our study suggests that imeglimin 1000 mg twice daily may offer the most optimum therapeutic effects for glycemic control without compromising its safety profiles.PMID:38047423 | DOI:10.1080/17446651.2023.2290488 (Source: Expert Review of Endocrinology and Metabolism)
Source: Expert Review of Endocrinology and Metabolism - December 4, 2023 Category: Endocrinology Authors: Hikmat Permana Nanny Natalia Mulyani Soetedjo Theo Audi Yanto Marshell Tendean Timotius Ivan Hariyanto Ketut Suastika Source Type: research